Literature DB >> 20800061

Differential expression of Toll-like receptors in follicular lymphoma, diffuse large B-cell lymphoma and peripheral T-cell lymphoma.

Thomas J Smith1, Kouhei Yamamoto, Morito Kurata, Akane Yukimori, Shiho Suzuki, Shigeaki Umeda, Emiko Sugawara, Yousuke Kojima, Motoji Sawabe, Yasunori Nakagawa, Kenshi Suzuki, James T B Crawley, Masanobu Kitagawa.   

Abstract

Although Toll-like receptors (TLRs) in mammals are well-known to play important roles in innate immunity, newer roles for the TLRs have suggested that cells with aberrant TLR expression may have a survival advantage over normal cells. Lymphocytes are one of a small number of cell types that express many of the TLRs, suggesting that abnormal TLR levels/signaling may potentially influence the progression of malignant lymphomas. Thus, frozen samples of 51 lymph nodes from patients with follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL) and peripheral T-cell lymphoma (PTCL) were analyzed for the expression of TLR1 to 9 using quantitative real-time PCR, and compared to those in reactive lymphadenopathy (RL) samples. TLR2 was over-expressed in both DLBCL and PTCL but not in FL when compared to RL. TLR1 and TLR4 expression was up-regulated in PTCL, while TLR8 was highly expressed in DLBCL. Although TLR5 showed lower expression in FL, expression of TLR3, TLR6, TLR7 and TLR9 did not vary significantly between different lymphoma subtypes. Double immunostaining revealed an increase in the number of TLR2 and/or TLR8 expressing lymphoma cells in DLBCL. In PTCL, TLR2 and TLR4 expression was localized to neoplastic T cells. TLR expression is highly variable among lymphoma subtypes. However, despite this some significant differences exist that may prove useful in the development of novel therapeutic strategies.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20800061     DOI: 10.1016/j.yexmp.2010.08.003

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  10 in total

1.  Inhibition of IRAK1/4 sensitizes T cell acute lymphoblastic leukemia to chemotherapies.

Authors:  Zhaoyang Li; Kenisha Younger; Ronald Gartenhaus; Ann Mary Joseph; Fang Hu; Maria R Baer; Patrick Brown; Eduardo Davila
Journal:  J Clin Invest       Date:  2015-02-02       Impact factor: 14.808

Review 2.  Effects of Toll-like receptor signals in T-cell neoplasms.

Authors:  Cori Morrison; Maria R Baer; Dan P Zandberg; Amy Kimball; Eduardo Davila
Journal:  Future Oncol       Date:  2011-02       Impact factor: 3.404

3.  Lipopolysaccharide-induced toll-like receptor 4 signaling in cancer cells promotes cell survival and proliferation in hepatocellular carcinoma.

Authors:  Lili Wang; Rong Zhu; Zhiquan Huang; Haigang Li; Hongguang Zhu
Journal:  Dig Dis Sci       Date:  2013-07-05       Impact factor: 3.199

4.  Serum soluble toll-like receptor 2 and 4 as diagnostic and prognostic biomarkers for non-Hodgkin lymphoma.

Authors:  Nouran Fakhry; Ahmed Gowily; Tarek Okda; Maha Houssen
Journal:  Contemp Oncol (Pozn)       Date:  2020-10-30

5.  A role for TLR signaling during B cell activation in antiretroviral-treated HIV individuals.

Authors:  Basile Siewe; Ali Keshavarzian; Audrey French; Patricia Demarais; Alan Landay
Journal:  AIDS Res Hum Retroviruses       Date:  2013-08-16       Impact factor: 2.205

6.  TLR2-activated B cells are phenotypically similar to the abnormal circulating B cells seen preceding the diagnosis of AIDS-related NHL diagnosis.

Authors:  Yu Guo; Basile Siewe; Marta Epeldegui; Roger Detels; Alan L Landay; Otoniel Martínez-Maza
Journal:  J Acquir Immune Defic Syndr       Date:  2013-10-01       Impact factor: 3.731

Review 7.  Toll-like receptors in the pathogenesis of human B cell malignancies.

Authors:  Johana M Isaza-Correa; Zheng Liang; Anke van den Berg; Arjan Diepstra; Lydia Visser
Journal:  J Hematol Oncol       Date:  2014-08-12       Impact factor: 17.388

8.  Local administration of a novel Toll-like receptor 7 agonist in combination with doxorubicin induces durable tumouricidal effects in a murine model of T cell lymphoma.

Authors:  Jiang Zhu; Shiping He; Jie Du; Zhulin Wang; Wang Li; Xianxiong Chen; Wenqi Jiang; Duo Zheng; Guangyi Jin
Journal:  J Hematol Oncol       Date:  2015-03-04       Impact factor: 17.388

9.  Elevated expression of TLR2 and its correlation with disease activity and clinical manifestations in adult-onset Still's disease.

Authors:  Jae Ho Han; Mi-Hyun Ahn; Ju-Yang Jung; Ji-Won Kim; Chang-Hee Suh; Ji Eun Kwon; Hyunee Yim; Hyoun-Ah Kim
Journal:  Sci Rep       Date:  2022-06-17       Impact factor: 4.996

10.  Synergy of purine-scaffold TLR7 agonist with doxorubicin on systemic inhibition of lymphoma in mouse model.

Authors:  Dong Gao; Wang Li; Wanmin Wang; Yongguang Cai; Yuhuan Wang; Xiaoling Luo; Chih-Chang Wei
Journal:  J Cancer       Date:  2017-09-15       Impact factor: 4.207

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.